Oventus Medical Ltd (ASX:OVN) is pleased to announce that new clinical data from four separate studies on its Sleep Treatment Platform will be presented at Sleep DownUnder, the 30th annual meeting of sleep specialists, taking place in Brisbane between 17th -20th October.
This attached supplementary prospectus of Queensland Bauxite Ltd (ASX:QBL) has included some updated information on the original prospectus that was lodged with the ASIC on 27 September 2018.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce it has received a Notice of Intention to Grant a European patent covering the use of Progenza by the European Patent Office.
The Board of Queensland Bauxite Limited (ASX:QBL) is pleased to announce that its soon to be wholly owned subsidiary, Medcan Australia, has secured a Medical Cannabis Manufacture Licence under the ODC.
Anatara Lifesciences (ASX:ANR) is pleased to release its Annual Report, for the year ended 30th June 2018.
Melbourne based nasal respiratory company Rhinomed (ASX:RNO) (OTCMKTS:RHNMF) is pleased to advise investors it has signed a 12-year exclusive licensing agreement of its nasal platform technology with Columbia Care LLC, the largest and most experienced provider of cannabis-based products and services in the United States (U.S.).
Queensland Bauxite Ltd (ASX:QBL) Prospectus has been prepared for an offer of up to 170,000,000 new Shares at an issue price of $0.035 per Share to raise up to $5,950,000, with a minimum subscription of $1,995,000 together with one (1) free attaching Option for every two (2) Shares subscribed for and issued.
